Challenges and opportunities for development of an AIDS vaccine

Nature

Volumn 410, Issue 6831, 2001, Pages 1002-1007

  Nabel, G J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; ECONOMIC AND SOCIAL EFFECTS; VIRUSES;

HUMAN IMMUNODEFICIENCY VIRUS;

VACCINES;

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; TREATMENT PLANNING; VACCINE PRODUCTION; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; HIV; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0035912191     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35073500     Document Type: Review

References (96)

1. Cyototoxic T cell response to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
2. Extensive variation of human immunodeficiency virus type-1 in vivo
3. Reminiscences of Albert Sabin and his successful strategy for the development of the live oral poliovirus vaccine
4. Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1
5. Major transplantation antigens, viruses, and specificity of surveillance T cells
6. MHC-restricted cytotoxic T cells: Studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness
7. + T cell depletion in simian immunodeficiency virus-infected macaques
8. + lymphocytes
9. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
10. Endocytosis of major histocompatibility complex class 1 molecules is induced by the HIV-1 Nef protein
11. HIV-1 auxiliary proteins: Making connections in a dying cell
12. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
13. HIV-1 antibody - Debris or virion?
14. Neutralization of HIV-1 by antibody
15. A vaccine for HIV type 1: The antibody perspective
16. The antibody response in HIV-1 infection
17. Antibody-dependent enhancement of infection and the pathogenesis of viral disease
18. Human HIV vaccine trials: Does antibody-dependent enhancement pose a genuine risk?
19. Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials
20. Sequence comparison of the phosphoprotein mRNAs of antigenic subgroups A and B of human respiratory syncytial virus identifies a highly divergent domain in the predicted protein
21. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
22. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
23. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
24. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
25. Pathogenicity, of live, attenuated SIV after mucosal infection of neonatal macaques
26. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
27. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
28. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients
29. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1
30. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1
31. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection
32. HIV infection and pathogenesis: What about chemokines?
33. Beta-chemokines and protection from HIV type 1 disease
34. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene
35. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
36. Progress in the development of an HIV-1 vaccine
37. DNA vaccines
38. Gene vaccination: Plasmid DNA is more than just a blueprint
39. Genetic immunization is a simple method for eliciting an immune response
40. Vaccination of mice and nonhuman primates using HIV-gene-containing DNA
41. DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen-expressing cells
42. Heterologous protection against influenza by injection of DNA encoding a viral protein
43. Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines
44. + cell-, interferon gamma-, and nitric oxide-dependent immunity
45. DNA vaccines against malaria: Immunogenicity and protection in a rodent model
46. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein
47. Vaccination against tuberculosis by injection
48. Immunization for Ebola virus infection
49. DNA immunization protects nonhuman primates against rabies virus
50. DNA vaccination against persistent viral infection
51. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection
52. Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27
53. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
54. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
55. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression
56. Increased immune response elicited by DNA vaccination with a synthetic gp 120 sequence with optimized codon usage
57. Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
58. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates
59. Poxvirus-based vectors as vaccine candidates
60. Evaluation of recombinant alphaviruses as vectors in gene therapy
61. Sindbis virus vectors for expression in animal cells
62. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
63. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy
64. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
65. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery
66. Lentiviral vectors: Turning a deadly foe into a therapeutic agent
67. AAV vectors: Is clinical success on the horizon?
68. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus
69. Adjuvants - A classification and review of their modes of action
70. Importance of the nef gene for maintenance of high virus loads and for development of AIDS
71. HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology
72. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
73. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
74. A controversial shot in the arm
75. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
76. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
77. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates
78. Core structure of gp41 from the HIV envelope glycoprotein
79. Atomic structure of the ectodomain from HIV-1 gp41
80. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain
81. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
82. Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket
83. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
84. Human studies in the development of human immunodeficiency virus vaccines
85. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
86. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
87. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
88. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression